EGFR and non-small cell lung carcinoma: Another recent paper directly implicated epigenetic alterations, including increased expression of the histone demethylase, JARID1A/KDM5A, and loss of H3K4me2/me3 histone marks, in tolerance of a mutant EGFR NSCLC line to EGFR targeted therapy, and demonstrated the ability to prevent or suppress the phenotype through treatment with HDIs [18].